Cargando…
Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
Optimization of post‐remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents...
Autores principales: | Medeiros, Bruno C., Chan, Steven M., Daver, Naval G., Jonas, Brian A., Pollyea, Daniel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593671/ https://www.ncbi.nlm.nih.gov/pubmed/30945331 http://dx.doi.org/10.1002/ajh.25484 |
Ejemplares similares
-
New directions for emerging therapies in acute myeloid leukemia: the next chapter
por: Daver, Naval, et al.
Publicado: (2020) -
The changing face of acute myeloid leukemia therapeutics in the elderly population
por: Daver, Naval, et al.
Publicado: (2015) -
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021) -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019) -
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
por: Daver, Naval, et al.
Publicado: (2021)